FOTIVDA
Total Payments
$118.4M
Transactions
18,280
Doctors
6,097
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $111.0M | 5,905 | 3,235 |
| 2023 | $5.5M | 6,148 | 2,682 |
| 2022 | $1.5M | 4,930 | 2,656 |
| 2021 | $513,552 | 1,297 | 1,036 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $117.0M | 3,498 | 98.8% |
| Food and Beverage | $337,694 | 12,695 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $323,679 | 138 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $236,603 | 93 | 0.2% |
| Consulting Fee | $157,388 | 99 | 0.1% |
| Honoraria | $147,789 | 97 | 0.1% |
| Education | $91,542 | 1,284 | 0.1% |
| Travel and Lodging | $86,053 | 320 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $60,000 | 21 | 0.1% |
| Entertainment | $4,820 | 35 | 0.0% |
Payments by Type
Research
$117.0M
3,498 transactions
General
$1.4M
14,782 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | Aveo Pharmaceuticals, Inc. | $115.1M | 8 |
| A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | Aveo Pharmaceuticals, Inc. | $1.5M | 7 |
| Phase II Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (FORTUNE) | Aveo Pharmaceuticals, Inc. | $135,447 | 0 |
| Atezolizumab plus Tivozanib in Immunologically Cold Tumor Types (IMMCO-1) | Aveo Pharmaceuticals, Inc. | $98,023 | 0 |
| A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma | Aveo Pharmaceuticals, Inc. | $82,484 | 0 |
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | AVEO Pharmaceuticals, Inc. | $19,445 | 0 |
Top Doctors Receiving Payments for FOTIVDA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Jessa Suhner | — | New York, NY | $116.9M | 3,465 |
| , M.D | Hematology & Oncology | Cary, NC | $154,980 | 209 |
| , MD | Medical Oncology | Fort Worth, TX | $89,748 | 101 |
| , M.D | Hematology & Oncology | Milwaukee, WI | $80,750 | 54 |
| , MD | Internal Medicine | San Diego, CA | $76,923 | 77 |
| Randy Sweis | Hematology & Oncology | Chicago, IL | $52,356 | 48 |
| , MD | Internal Medicine | Dallas, TX | $44,425 | 2 |
| , M.D | Hematology & Oncology | Port Jefferson Station, NY | $33,411 | 36 |
| , MD | Internal Medicine | San Antonio, TX | $33,266 | 10 |
| , DO,PHARMD | Medical Oncology | Dallas, TX | $32,960 | 26 |
| , M.D | Medical Oncology | Baltimore, MD | $28,920 | 10 |
| , MD | Internal Medicine | Santa Monica, CA | $27,833 | 25 |
| , M.D | Hematology & Oncology | Goodyear, AZ | $27,270 | 19 |
| Ghazal Jameel | Nurse Practitioner | Tampa, FL | $25,468 | 66 |
| David Gill | Medical Oncology | Salt Lake City, UT | $18,828 | 14 |
| , M.D | Internal Medicine | Chicago, IL | $18,242 | 2 |
| , MD | Medical Oncology | Bronx, NY | $13,465 | 2 |
| Michael Lattanzi | Medical Oncology | New York, NY | $13,056 | 15 |
| , M.D | Internal Medicine | San Francisco, CA | $10,894 | 9 |
| , MD | Hematology & Oncology | La Jolla, CA | $10,619 | 12 |
| , M.D | Medical Oncology | Boston, MA | $9,644 | 3 |
| , M.D | Internal Medicine | Houston, TX | $8,775 | 1 |
| , MD | Medical Oncology | Detroit, MI | $7,983 | 9 |
| , M.D | Hematology & Oncology | New Orleans, LA | $7,784 | 11 |
| , MD | Hematology & Oncology | Boston, MA | $7,546 | 7 |
Ad
Manufacturing Companies
- Aveo Pharmaceuticals, Inc. $117.6M
- AVEO Pharmaceuticals, Inc. $782,621
Product Information
- Type Drug
- Total Payments $118.4M
- Total Doctors 6,097
- Transactions 18,280
About FOTIVDA
FOTIVDA is a drug associated with $118.4M in payments to 6,097 healthcare providers, recorded across 18,280 transactions in the CMS Open Payments database. The primary manufacturer is Aveo Pharmaceuticals, Inc..
Payment data is available from 2021 to 2024. In 2024, $111.0M was paid across 5,905 transactions to 3,235 doctors.
The most common payment nature for FOTIVDA is "Unspecified" ($117.0M, 98.8% of total).
FOTIVDA is associated with 6 research studies, including "TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor" ($115.1M).